Skip to content

DRUG - BRIGHT MINDS BIOSCIENCES INC. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchD

Bright Minds Biosciences Inc

DRUG · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

D

DRUGBright Minds Biosciences Inc

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 20

52-wk high: $123.75
52-wk low: $38.00
Prev close: $78.64
Mkt cap: $831.5M
Beta: 0.09
P/B: 3.7x

Smart money

8 funds hold a position and insiders have been net selling.

Real smart money

Funds holding this stock

8 holders

Combined position$122.6M

BA
Balyasny
Dmitry Balyasny · Q2 2026 13F
$24.2M
position
P7
Point72
Steven Cohen · Q2 2026 13F

Earnings

Reported Aug 13, 2026

Earnings came in 87.8% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is running thin margins.

Net margin: 0.0%
Market cap: $831M

Valuation

P/B3.73

Quality

Operating margin0.0%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: DRUG
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $831.47M
Beta: 0.09

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

Profit margin

+0.0%

Op margin

+0.0%

ROE

-13.6%

$23.0M

position

MI

Millennium

Israel Englander · Q2 2026 13F

$4.7M

position

5 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 5 holders

Coverage gaps for DRUG

No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.17+87.8%

-$1.39 expected

Next report

What the street expects next

EPS expected

-$1.70

-$3.22 to -$0.41

Revenue expected

$0.00

7 analysts

Last 30 days

2up3down

Analysts cutting estimates

Estimate drift

+0.46

Change in 30 days

-13.6%

ROA-13.5%

Growth

Beta0.09